Gregg J. SilvermanProfessor | New York, New York
Dr. Silverman has been involved in studies of autoantibodies since the time of his fellowship at the Scripps Research Foundation in 1986. Working in the laboratory of Prof. Dennis Carson, these studies began with clinical samples from the laboratory of Henry Kunkel (Rockefeller Institute), the father of modern clinical immunology and the analysis of antibody gene usage in human rheumatoid factors from patients with essential mixed cryoglobulinemia, Hepatitis C, Rheumatoid Arthritis, and Sjogrens syndrome. These studies later evolved into investigations of the human B-cell repertoire and the response to B-cell superantigens, which can result in supra-clonal expansions or programmed cell death.
From earlier collaborative studies with the laboratory of Joseph Witztum (UC San Diego), we have subsequently developed new insights into the immunomodulatory properties of B-cells as producers of protective autoantibodies to apoptotic cell membrane determinants that may oppose the development of inflammatory and autoimmune diseases. Recent work has led to the development of the Dual inhibitor receptor hypothesis, which provides a theoretical model to explain the molecular mechanisms of natural antibody mediated clearance of apoptotic cells and immune modulation. For more than a decade, Dr. Silverman has also directed an annual coure of phage display and recombinant antibody technology at Cold Spring Harbor Labs.
Dr. Silverman is also a practicing rheumatologist with a special interest in caring for patients with lupus, rheumatoid arthritis, and related conditions. After more than two decades on the faculty at UCSD, Dr. Silverman moved to NYU School of Medicine in early 2011.